Thermo Fisher Scientific to Acquire QIAGEN N.V.
. Expands specialty diagnostics portfolio with attractive molecular diagnostics capabilities, including infectious di…
. Expands specialty diagnostics portfolio with attractive molecular diagnostics capabilities, including infectious di…
. - Q3 2013 results: Adjusted net sales $323.8 million (+7% CER) on growth in all regions and customer classes; adjuste…
Q2 2013 results: Adjusted net sales of $316.4 million (+3% CER) on growth in all regions; adjusted operating income of $…
. Achieves Q1 2013 targets: Net sales of $303.6 million grow 3% CER on expansion in all regions; adjusted diluted EPS…
. QIAGEN exceeds Q4 and full-year 2012 targets: - Full-year 2012: Net sales advance 10% CER (+7% reported) to $1.…
. - Delivering solid results in third quarter of 2012: Net sales rise 10% CER (+5% reported) to $304.3 million on growt…
. - Solid performance in second quarter of 2012: Net sales rise 9% (+14% CER) to $307.2 million on growth in all custom…
. - QIAGEN expands Point of Need portfolio with unique AmniSure® assay to detect rupture of fetal membranes (ROM) - che…
. - Net sales rise 12% (+13% CER) to $296.4 million, adjusted operating income advances 14% to $80.3 million and adjust…
. - Significant progress on strategic initiatives to drive growth and innovation: - Driving platform success: More…